Interstitial Lung Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Interstitial Lung Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

The 7 major interstitial lung disease markets reached a value of US$ 1.2 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 2.1 Billion by 2034, exhibiting a growth rate (CAGR) of 4.99% during 2024-2034.

The interstitial lung disease market has been comprehensively analyzed in IMARC's new report titled "Interstitial Lung Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Interstitial lung disease (ILD) is a respiratory ailment that causes progressive scarring and inflammation of lung tissue. The scarring associated with this condition makes the lung tissue stiff, resulting in impaired breathing and inadequate oxygen supply to the bloodstream. Individuals suffering from this disorder may experience shortness of breath, fatigue, non-productive coughing, and gradual weight loss, which tend to develop over several months. As ILD progresses, symptoms may worsen, including persistent cough, wheezing, weight loss, difficulty breathing even while resting, etc. In some cases, the disease may cause clubbing of the fingertips or a bluish tinge to the skin due to poor oxygenation. The diagnosis of this ailment generally involves a review of the patient's symptoms, medical history, and laboratory tests. A blood test is carried out to detect antibodies, proteins, and other markers of inflammatory responses to environmental exposures. Additionally, computerized tomography (CT) scans and echocardiogram are primarily performed to confirm a diagnosis. The healthcare professional may also recommend bronchoscopy, bronchoalveolar lavage, and surgical biopsy among patients to identify the condition.

The increasing prevalence of lung disorders caused by air pollution, smoking, and exposure to hazardous materials, such as coal dust and asbestos, is primarily driving the interstitial lung disease market. Apart from this, the rising incidences of autoimmune ailments, including rheumatoid arthritis, scleroderma, lupus, etc., which cause inflammation and scarring in the lungs, leading to ILD, are also bolstering the market growth. Furthermore, the widespread adoption of corticosteroids as a treatment option for ILD, since it stabilizes or reduces disease progression by limiting the number of inflammatory compounds in the lungs, is creating a positive outlook for the market. Besides this, the escalating utilization of pulmonary tyrosine kinase inhibitors, which block numerous pathways leading to scar tissue formation, is also augmenting the market growth. Moreover, multiple key players are making extensive investments to launch novel therapies that can improve lung function and patient well-being. This, in turn, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of anti-fibrotic medications that can slow the decline in lung function and reduce the risk of acute exacerbations, thereby improving the quality of life for patients, is expected to drive the interstitial lung disease market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the interstitial lung disease market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for interstitial lung disease and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the interstitial lung disease market in any manner.

Time Period of the Study

Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the interstitial lung disease market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the interstitial lung disease market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current interstitial lung disease marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance.

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:
Market Insights

How has the interstitial lung disease market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the interstitial lung disease market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the interstitial lung disease market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (​2018-2034​) of interstitial lung disease across the seven major markets?
What is the number of prevalent cases (​2018-2034​) of interstitial lung disease by age across the seven major markets?
What is the number of prevalent cases (​2018-2034​) of interstitial lung disease by gender across the seven major markets?
What is the number of prevalent cases (​2018-2034​) of interstitial lung disease by type across the seven major markets?
How many patients are diagnosed (​2018-2034​) with interstitial lung disease across the seven major markets?
What is the size of the interstitial lung disease patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of interstitial lung disease?
What will be the growth rate of patients across the seven major markets?

Interstitial Lung Disease: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for interstitial lung disease drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the interstitial lung disease market?
What are the key regulatory events related to the interstitial lung disease market?
What is the structure of clinical trial landscape by status related to the interstitial lung disease market?
What is the structure of clinical trial landscape by phase related to the interstitial lung disease market?
What is the structure of clinical trial landscape by route of administration related to the interstitial lung disease market?